A House subcommittee voted unanimously Thursday to send a bill intended to stop sham citizen petitions from clogging the FDA’s approval process for generic drugs under the section 505 pathway to the full Energy and Commerce Committee.
A House subcommittee voted unanimously Thursday to send a bill intended to stop sham citizen petitions from clogging the FDA’s approval process for generic drugs under the section 505 pathway to the full Energy and Commerce Committee.
The bipartisan bill, HR 2387, the Stop the Overuse of Petitions and Get Affordable Medicines to Enter Soon (STOP GAMES) Act of 2019, was introduced last spring by Representatives Andy Levin, D-Michigan, and Francis Rooney, R-Florida.
Citizen petitions are an avenue for any interested party to ask the FDA commissioner to change agency regulations or take—or refrain from taking—an administrative action. In the case of drug makers, such requests may include asking the FDA not to approve a generic or biosimilar product unless certain conditions are met.
Citizen petitions have nonetheless been the subject of controversy, as they require significant time and resources for the FDA to address. Among many stakeholders, there exists a consensus that brand-name drug makers could (and sometimes do) use these petitions to forestall competition from generic or biosimilar drugs.
In September, the FDA released final guidance to determine if citizen petitions are abusive.
If the bill becomes law, it would codify the FDA’s intent. It would allow the FDA to quickly reject a citizen petition submitted with the aim to stall a generic drug’s approval. It directs the HHS secretary to report such citizen petitions to the Federal Trade Commission and requires drug manufacturers to file a petition within 60 days of receiving actionable information. The bill also directs the FDA to report additional information to Congress, including: time and resources spent on each petition; timing of petitions relative to patent expiration; and any delay in approval of a competing generic drug caused by such petition.
America’s Health Insurance Plans (AHIP) submitted testimony on behalf of its member payer organizations, saying that while the FDA’s “petition process provides an opportunity to raise legitimate concerns about the safety and effectiveness of new drugs, it has also been exploited to delay or prevent the availability of more affordable generic drugs and biosimilars. This legislation takes important steps to curb abuses in the citizen petition process and remove barriers to the generic drugs that Americans need and deserve.”
Supporters of the bill say certain drug makers have abused the petition process to slow approvals and maintain monopolies.
However, on the other side of Congress this week, a bill called the Affordable Prescriptions for Patients Act did not advance, with Senator John Cornyn, R-Texas, accusing Senate Minority Leader Chuck Schumer, D-New York, of blocking the bill.
Cornyn and Senator Richard Blumenthal, D-Connecticut, introduced the bill, which aims to prevent patent thickets and product hopping, last spring. It has since gained other sponsors.
Schumer said the bill does not go far enough, according to a report, which also said that Schumer noted that Senate Majority Leader Mitch McConnell, R-Kentucky, had not scheduled any votes on any bills aimed at drug prices.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.